Ramesh Hariharan

Ramesh Hariharan is the current General Manager for Women's Health at Natera. Prior to this, they served as the Vice President of Marketing for bioTheranostics from April 2014 to April 2016. In this role, they were responsible for launching the company's breast cancer index, which is a commercial test that provides prognostic and predictive data to inform the extended endocrine treatment decision for ER+ patients. Ramesh also oversaw the launch of BioT3, a next gen sequencing and protein expression panel that is used to diagnose and treat metastatic NSCLC, Melanoma, Breast, Gastric and CRC patients. Prior to joining bioTheranostics, Hariharan served as the Senior Director of Oncology & Women's Health Marketing for AbbVie from March 2011 to April 2014. In this role, they were responsible for leading the global product launch of linifanib, which is an oral kinase inhibitor indicated for the treatment of various types of cancers. Ramesh also served as the Head of Women's Health & Pain franchise, where they oversaw the development of Elagolix, a GnRH antagonist indicated for the treatment of endometriosis and uterine fibroids, and launched Novartis' Global Brand Director & Head of New Products Marketing in January 2009.

Ramesh Hariharan has a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Bombay, an MBA in General Management from the MIT Sloan School of Management, and a Ph.D. in Chemical Engineering from Princeton University.

Some of their coworkers include J. Dianne Keen - Kim - CLIA Laboratory Director, Rishi Kacker - CTO, and Anu Pai - Head of R&D Program Management. Ramesh Hariharan reports to Steve Chapman, CEO.